多西他赛单周方案二线治疗非小细胞肺癌的疗效及安全性研究

Preliminary Study of Weekly Docetaxel as Second-line Chemotherapy for Advanced Non-small-cell Lung Cancer

目的探讨多西他赛单周方案二线治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法对32例ⅢB期或Ⅳ期的一线治疗失败的NSCLC患者给予多西他赛35mg/m2,第1、8天静脉输注。21天为1个周期,每例患者接受治疗2～6周期。结果 32例患者中,PR5例,SD例10例,疾病控制率为46.9%。中位PFS为3.8个月(95%CI:3.1～4.5个月),中位生存期为9.5个月(95%CI:7.8～11.2个月)。3～4级不良反应中,白细胞减少9例,脱发11例,恶心呕吐2例。结论多西他赛单周方案二线治疗NSCLC疗效确切,不良反应可以耐受。

Objective To evaluate the efficacy and safety of weekly docetaxel as second - line chemotherapy for advanced nonsmall cell lung cancer （NSCLC）. Methods Thirty - two patients with previously treated advanced NSCLC had been enrolled. All patients received regime of weekly d0cetaxel 35mg/m2on days 1 and 8. The regimen was given per 3 weeks. Results A total of 32 patients were evaluated for efficacy and toxicity. The disease control rate was 46.9% with partial responses and stable disease of 5 and 10, respectively. The median PFS and OS of all patients were 3.8 months （95% CI：3.1 -4.5） and 9.5 months（95% CI：7.8 - 11.2） , respectively. The main grade 3 - 4 toxicity consisted of leukopenia （9 patients） , phalacrosis （ ll patients） and nausea or vomiting （2 patients）. Conclusion Weekly docetaxel is an effective and well - tolerated scheme in the treatment of advanced NSCLC.